India Exchange Filings

Glenmark/IGI ISB 2301 IND Submission

Glenmark Pharmaceuticals Ltd’s Ichnos Glenmark Innovation submits U.S. FDA IND for solid-tumor candidate ISB 2301

  • ISB 2301 is an investigational multispecific immune cell activator targeting three tumor-associated antigens and engaging T cells and natural killer cells.
  • IGI plans to start a Phase 1 trial in patients with solid tumors in 2027.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.